| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(1 year, 12 days from now) | |
| US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7141581 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Jun, 2020
(3 years ago) | |
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(10 years from now) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(12 years from now) | |
Inlyta is owned by Pf Prism Cv.
Inlyta contains Axitinib.
Inlyta has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Inlyta are:
- US7141581
Inlyta was authorised for market use on 27 January, 2012.
Inlyta is available in tablet;oral dosage forms.
Inlyta can be used as treatment of renal cell carcinoma, axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma, in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma.
Drug patent challenges can be filed against Inlyta from 28 January, 2016.
The generics of Inlyta are possible to be released after 12 January, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: Treatment of renal cell carcinoma; In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-li...
Dosage: TABLET;ORAL
INLYTA family patents
